Abstract
The prevalence and persistence of adaptive immunity responses following a SARS-CoV-2 infection provides insights into potential population immunity. Adaptive immune responses comprise of antibody-based responses as well as T cell responses mainly addressing viruses and virus-infected human cells, respectively. A comprehensive analysis of both types of adaptive immunity is essential to follow population-based SARS-CoV-2-specific immunity. In this study, we assessed SARS-CoV-2-specific immunoglobulin A (IgA) levels, SARS-CoV-2-specific immunoglobulin G (IgG) levels, and SARS-CoV-2-specific T cell activities in patients who recovered from a COVID-19 infection in spring and autumn 2020. Here we observed a robust and stable SARS-CoV-2-specific adaptive immune response in both groups with persisting IgA and IgG levels as well as stable T cell activity. Moreover, there was a positive correlation of a lasting immune response with the severity of disease. Our data give evidence for a persisting adaptive immune memory, which suggest a continuing immunity for more than six months post infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
University-internal funding only
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local ethical comittee of the Danube Private University, Krems/Donau, Austria, (Kommission fuer wissenschaftliche Integritaet und Ethik, Head: Univ. Prof. Mag. Dr. Wilhelm Frank MLS, ethikkommission@dp-uni.ac.at) approved on Dec 1st, 2020 that our study follows all relevant ethical guidelines (reference DPU-EK/0003).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available from the authors upon request
